Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Growth (Status and Outlook) 2023-2029

Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Growth (Status and Outlook) 2023-2029

A biomarker is, according to the US National Institutes of Health, “a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention.”
Biomarkers make take the form of cellular characteristics, metabolites (e.g. sugars, lipids and hormones), molecular variations, or physical features (e.g., clinical symptoms) and are assessed accordingly, via measurement, annotation, documents, and images.
Increasingly, the discovery of novel biomarkers is closely associated with the advances in molecular biology techniques that can be accessed through analysis of DNA, RNA or proteins.
We can discriminate four main types of molecular biomarkers:
• Genomic biomarkers: Based on the analysis of DNA (deoxyribonucleic acid) profiles, especially the analysis of SNPs (single nucleotide polymorphisms), i.e. identification of punctual variations in genomic DNA.
• Transcriptomic biomarkers: Base on the analysis of RNA expression profiles.
• Proteomic biomarkers: Base on the analysis of the protein profiles.
• Metabolomic biomarkers: Base on the analysis of metabolites (metabolites are the intermediates and products of metabolism).

Commercializing biomarkers is the path that a biomarker could be used in therapeutic or diagnostic. In this report mainly covers consumables, services, software of this market.
LPI (LP Information)' newest research report, the “Commercializing Biomarkers in Therapeutic and Diagnostic Applications Industry Forecast” looks at past sales and reviews total world Commercializing Biomarkers in Therapeutic and Diagnostic Applications sales in 2022, providing a comprehensive analysis by region and market sector of projected Commercializing Biomarkers in Therapeutic and Diagnostic Applications sales for 2023 through 2029. With Commercializing Biomarkers in Therapeutic and Diagnostic Applications sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Commercializing Biomarkers in Therapeutic and Diagnostic Applications industry.
This Insight Report provides a comprehensive analysis of the global Commercializing Biomarkers in Therapeutic and Diagnostic Applications landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Commercializing Biomarkers in Therapeutic and Diagnostic Applications portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Commercializing Biomarkers in Therapeutic and Diagnostic Applications market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Commercializing Biomarkers in Therapeutic and Diagnostic Applications and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Commercializing Biomarkers in Therapeutic and Diagnostic Applications.
The global Commercializing Biomarkers in Therapeutic and Diagnostic Applications market size is projected to grow from US$ 20920 million in 2022 to US$ 29400 million in 2029; it is expected to grow at a CAGR of 5.0% from 2023 to 2029.
The major players in global Commercializing Biomarkers in Therapeutic and Diagnostic Applications market include Roche, Dako (Agilent Technologies), Affymetrix, etc. The top 3 players occupy about 10% shares of the global market. North America and Europe are main markets, they occupy about 70% of the global market. Consumables is the main type, with a share about 60%. The main applications include Oncology, Cardiology, Neurology, etc.
This report presents a comprehensive overview, market shares, and growth opportunities of Commercializing Biomarkers in Therapeutic and Diagnostic Applications market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Consumables
Services
Software
Segmentation by application
Oncology
Cardiology
Neurology
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Roche
Dako (Agilent Technologies)
Merck
BD
Abbott
Genesys Biolabs (20/20GeneSystems)
Affymetrix
Agendia
ALMAC
Arrayit
Biocartic
BG Medicine
KEGG EXPRESSION Database
Thermo Fisher
BGI

Please note: The report will take approximately 2 business days to prepare and deliver.